… -based targets for oral antivirals development to treat COVID-19, highlight and compare the
main features, advantages, and limitations of the first-generation oral antiviral therapeutics (…

… distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), …
, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…

… In an open-label, controlled study of 80 patients with laboratory-confirmed COVID-19, 35
patients who received oral favipravir plus interferon (IFN)-α by aerosol inhalation were …

… Therefore, a specific medication therapy for COVID-19 is … , among the current treatment
options, systemic antivirals are the … to summarize ongoing antiviral treatments in COVID-19, to …

… In addition, we analysed the efficacy of three different antiviral drugs for COVID-19 patients,
and the OR was 0.22 (95% CI, 0.10–0.48) in the molnupiravir group, 0.45 (95% CI, 0.28–0.72…

… Antiviral therapies that reduce the risk of Covid-19 progression are needed. Since trials have
shown the need for initiation of treatment as soon as possible after the onset of symptoms, 7…

… COVID-19, the need to confine the pandemic and treat infected individuals on an outpatient
basis has led to the approval of oral antiviral … , delivered as an oral formulation, has shown …

… of influenza and is being explored more for its role in the treatment of COVID-19. It is the first
oral antiviral drug approved for mild to moderate COVID-19. The already completed studies …

… Covid-19 patients with severe renal or hepatic impairment. Preliminary studies showed oral
antiviral drugs … four monoclonal antibodies for Covid-19 treatment. Studies suggest that these …

… This article reviews the 2 oral COVID-19 antiviral drugs including the mechanisms of action,
… the 2 oral COVID-19 antiviral drugs including the mechanisms of action, antiviral activity, …